BiomX Inc. Issues 8-K: Convertible Note Conversion, Share Issuance, and New Financing Terms
Summary of Key Events
- Issuance of Restricted Shares: BiomX Inc. has issued 1,013,637 restricted shares of common stock to three individual assignees upon partial conversion of an outstanding convertible promissory note.
- Convertible Promissory Note Details: The note was originally issued to Mandragola Ltd. and carries a 12% annual interest rate. The conversion is a result of a financing arrangement, possibly indicating ongoing liquidity management.
- Warrant Issuance: Alongside the credit line, Mandragola Ltd. received a warrant to purchase 2,000,000 shares of common stock at terms specified in the attached warrant agreement.
- Trading Symbol and Exchange: BiomX Inc.’s common stock trades under the symbol PHGE on the NYSE American.
- Emerging Growth Company Status: BiomX is not classified as an emerging growth company under current SEC definitions.
- Shareholder Dilution and Price Impact: The issuance of new shares and warrants may be materially dilutive to existing shareholders and could affect share price depending on subsequent conversion and exercise activity.
Details Investors Must Know
Convertible Note and Share Issuance
BiomX Inc. completed a partial conversion of a previously issued convertible promissory note, resulting in the issuance of over one million restricted common shares. This conversion was made to three individual assignees, and the original noteholder, Mandragola Ltd., is a company formed under the laws of the State of Israel. The conversion price and further terms are not specified in the summary, but the note itself bears a 12% annual interest rate.
Why this matters: The issuance of new restricted shares increases the total number of shares outstanding and, unless offset by value-creating activities, may dilute the value of existing shares. Investors should monitor developments further, especially if additional conversions or share issuances occur under similar terms.
Warrant Terms
As part of the financing package, Mandragola Ltd. received a warrant to purchase 2,000,000 shares of common stock. The warrant includes standard anti-dilution provisions:
- If BiomX subdivides its common stock (stock splits, dividends, recapitalizations), the exercise price will be adjusted downward.
- If BiomX combines its common stock (reverse splits), the exercise price will be adjusted upward.
- For other actions potentially diluting warrant holders, adjustments will be made by the board or by independent investment banks if disputes arise.
- Warrant shares must be reserved equal to 250% of the maximum number of shares issuable under the warrant, ensuring the company has enough authorized shares.
Why this matters: The warrant, if exercised, could result in a further significant increase in shares outstanding. Investors should be aware of the potential for dilution and the effect on share price if the warrant is exercised, especially if it is “in the money.”
Credit Line Agreement
The company entered into a credit line agreement with Mandragola Ltd. on May 13, 2026. The full terms are included as an exhibit, but the existence of this agreement suggests BiomX is actively managing its liquidity and capital needs. The conversion feature and the warrant are key elements of this financing structure.
SEC Compliance and Shareholder Communication
BiomX Inc. has not checked any boxes indicating that this 8-K is intended to satisfy obligations relating to written communications, soliciting material, or pre-commencement tender offers. This means the filing is strictly for disclosure of the share issuance and related financial agreements.
Potential Price-sensitive Factors
- Share Dilution: The issuance of over 1 million shares and the potential exercise of warrants for 2 million shares can be highly dilutive. This is a significant event for shareholders, as it may impact the share price.
- Convertible Note Conversion: The conversion of debt into equity often signals company needs for liquidity or capital structure adjustment. Investors should watch for further such conversions, which could signal ongoing capital needs.
- Warrant Exercise Risk: If the stock price rises, warrant holders may exercise, further increasing the float and diluting ownership.
- Material Agreements: The exhibits attached (Form of Note, Warrant, Credit Line Agreement) provide specifics on the terms, which investors should review for additional risks or opportunities.
Exhibits and Attachments
- Exhibit 4.1: Form of 12% Convertible Promissory Note
- Exhibit 4.2: Warrant to Purchase Common Stock, dated May 13, 2026
- Exhibit 10.1: Line of Credit Agreement between BiomX Inc. and Mandragola Ltd.
- Exhibit 104: Cover Page Interactive Data File (embedded within the Inline XBRL document)
Company Information
- Name: BiomX Inc.
- Trading Symbol: PHGE
- Exchange: NYSE American
- Date of Report: June 2, 2026
- Chief Executive Officer: Michael Oster
Conclusion & Investor Takeaways
The issuance of new shares and warrants, as well as the conversion of a substantial debt instrument into equity, are material events that may affect BiomX Inc.’s share price and capital structure. Investors should review the attached exhibits for full details and monitor the company for further conversions or warrant exercises, which could further increase dilution. The company’s liquidity management via the credit line and convertible note is a signal of ongoing capital needs.
